This page shows the latest CRPC news and features for those working in and with pharma, biotech and healthcare.
CRPC, and a 52% prostate-specific antigen (PSA) response.
The COSMIC-021 trial evaluated the combination treatment in patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), whose disease had progressed on prior novel hormone therapy. ... Exelixis intends to file the
First approval could give Clovis an opportunity to build familiarity with its brand among clinicians treating CRPC before its big pharma rivals reach the market, although its rivals are hot on ... the first half of 2020, while GSK/J&J have also reported
For Pfizer, the potential approval in this indication could help drive Xtandi's growth even further – the drug picked up an approval in castration-resistant prostate cancer (CRPC) with non-metastatic ... CRPC last year.
Meanwhile, Zytiga – which is only approved for metastatic CRPC – pulled in $3.5bn last year, but the start of generic competition in late 2018 was evident in a 21% slump in
subpopulation of HRRms – namely BRCA1/BRCA2 and ATM mutations – and that makes PROfound “the only positive phase 3 trial of any PARP inhibitor” in CRPC. ... AZ is also conducting a phase 3 trial (PROPEL) of Lynparza in combination with Zytiga as
More from news
Approximately 1 fully matching, plus 42 partially matching documents found.
In patients with non-metastatic CRPC, there is a high unmet need to delay development of metastases and the progression to advanced prostate cancer. ... for approval in the US and EU for non-metastatic CRPC on the strength of MFS data from the PROSPER
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...